We found that t(8;21) AML patients without c-KIT mutation (n = 3, Pt# 1–3, Additional file 2: Table S1) exhibited a notable decrease in FTO mRNA levels upon achieving complete remission (CR); however, this phenomenon was not observed in patients with c-KIT mutation (n = 3, Pt# 4–6, Additional file 2: Table S1; Fig. 1C). This evidence concerns the gene KIT and acute myeloid leukemia.